Table 4.

Relationship between percent GATA2+ blasts and survival in adult AML

AML groupOS (mos)
Median (95% CI)
GATA2 hazard ratio (95% CI) P value
Overall (n = 68) 8.4 (5.4-12.9) 0.93 (0.55-1.50) .768 
Curative intent    
No (n = 41) 4.0 (2.6-5.8) 1.13 (0.57-2.13) .720 
Yes (n = 27) 21.0 (12.7, —) 0.80 (0.29-1.89) .619 
Allogeneic HSCT    
No (n = 46) 4.1 (2.7-8.4) 1.00 (0.49-1.96) .997 
Yes (n = 22) 17.7 (10.3, —) 0.88 (0.34-1.94) .759 
AML groupOS (mos)
Median (95% CI)
GATA2 hazard ratio (95% CI) P value
Overall (n = 68) 8.4 (5.4-12.9) 0.93 (0.55-1.50) .768 
Curative intent    
No (n = 41) 4.0 (2.6-5.8) 1.13 (0.57-2.13) .720 
Yes (n = 27) 21.0 (12.7, —) 0.80 (0.29-1.89) .619 
Allogeneic HSCT    
No (n = 46) 4.1 (2.7-8.4) 1.00 (0.49-1.96) .997 
Yes (n = 22) 17.7 (10.3, —) 0.88 (0.34-1.94) .759 

AML, acute myeloid leukemia; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; OS, overall survival.

Hazard ratio for a 1 interquartile range increase in percent GATA2+ blasts (from 5%-60%).

Close Modal

or Create an Account

Close Modal
Close Modal